vs
Side-by-side financial comparison of Azenta, Inc. (AZTA) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $148.6M, roughly 1.4× Azenta, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -10.4%, a 67.8% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $14.7M).
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
AZTA vs IDYA — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.6M | $207.8M |
| Net Profit | $-15.4M | $119.2M |
| Gross Margin | 42.9% | — |
| Operating Margin | -4.9% | 52.2% |
| Net Margin | -10.4% | 57.4% |
| Revenue YoY | 0.8% | — |
| Net Profit YoY | -15.7% | 330.1% |
| EPS (diluted) | $-0.34 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.6M | — | ||
| Q3 25 | $159.2M | $207.8M | ||
| Q2 25 | $143.9M | — | ||
| Q1 25 | $143.3M | — | ||
| Q4 24 | $147.4M | — | ||
| Q3 24 | $150.6M | $0 | ||
| Q2 24 | $144.3M | $0 | ||
| Q1 24 | $136.4M | $0 |
| Q4 25 | $-15.4M | — | ||
| Q3 25 | $50.9M | $119.2M | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-47.7M | — | ||
| Q4 24 | $-11.0M | — | ||
| Q3 24 | $-6.6M | $-51.8M | ||
| Q2 24 | $-6.6M | $-52.8M | ||
| Q1 24 | $-137.4M | $-39.6M |
| Q4 25 | 42.9% | — | ||
| Q3 25 | 45.4% | — | ||
| Q2 25 | 46.2% | — | ||
| Q1 25 | 43.8% | — | ||
| Q4 24 | 46.7% | — | ||
| Q3 24 | 45.5% | — | ||
| Q2 24 | 44.8% | — | ||
| Q1 24 | 43.8% | — |
| Q4 25 | -4.9% | — | ||
| Q3 25 | 1.2% | 52.2% | ||
| Q2 25 | -1.3% | — | ||
| Q1 25 | -12.7% | — | ||
| Q4 24 | -5.9% | — | ||
| Q3 24 | -3.1% | — | ||
| Q2 24 | -4.9% | — | ||
| Q1 24 | -18.1% | — |
| Q4 25 | -10.4% | — | ||
| Q3 25 | 32.0% | 57.4% | ||
| Q2 25 | -33.4% | — | ||
| Q1 25 | -33.3% | — | ||
| Q4 24 | -7.5% | — | ||
| Q3 24 | -4.4% | — | ||
| Q2 24 | -4.5% | — | ||
| Q1 24 | -100.8% | — |
| Q4 25 | $-0.34 | — | ||
| Q3 25 | $1.12 | $1.33 | ||
| Q2 25 | $-1.05 | — | ||
| Q1 25 | $-1.04 | — | ||
| Q4 24 | $-0.25 | — | ||
| Q3 24 | $-0.25 | $-0.60 | ||
| Q2 24 | $-0.12 | $-0.68 | ||
| Q1 24 | $-2.48 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $336.6M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.7B | $1.1B |
| Total Assets | $2.1B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $336.6M | — | ||
| Q3 25 | $279.8M | $786.9M | ||
| Q2 25 | $270.0M | — | ||
| Q1 25 | $253.6M | — | ||
| Q4 24 | $377.5M | — | ||
| Q3 24 | $280.0M | $920.0M | ||
| Q2 24 | $336.5M | $701.7M | ||
| Q1 24 | $353.5M | $698.8M |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.8B | $1.2B | ||
| Q2 24 | $2.0B | $931.7M | ||
| Q1 24 | $2.2B | $935.3M |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.1B | $1.2B | ||
| Q2 24 | $2.3B | $973.7M | ||
| Q1 24 | $2.6B | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.8M | $142.2M |
| Free Cash FlowOCF − Capex | $14.7M | $142.2M |
| FCF MarginFCF / Revenue | 9.9% | 68.4% |
| Capex IntensityCapex / Revenue | 4.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $30.9M | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.8M | — | ||
| Q3 25 | $2.2M | $142.2M | ||
| Q2 25 | $25.8M | — | ||
| Q1 25 | $14.4M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $17.7M | $-49.2M | ||
| Q2 24 | $9.8M | $-32.9M | ||
| Q1 24 | $8.7M | $-43.8M |
| Q4 25 | $14.7M | — | ||
| Q3 25 | $-5.7M | $142.2M | ||
| Q2 25 | $15.0M | — | ||
| Q1 25 | $7.0M | — | ||
| Q4 24 | $22.0M | — | ||
| Q3 24 | $8.3M | $-49.7M | ||
| Q2 24 | $1.3M | $-33.9M | ||
| Q1 24 | $428.0K | $-45.1M |
| Q4 25 | 9.9% | — | ||
| Q3 25 | -3.6% | 68.4% | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | 4.9% | — | ||
| Q4 24 | 15.0% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 4.2% | — | ||
| Q3 25 | 4.9% | 0.0% | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 5.2% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 6.2% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 6.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.04× | 1.19× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
IDYA
Segment breakdown not available.
